Bank of America Corp DE Has $36.97 Million Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Bank of America Corp DE raised its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 780.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,764,455 shares of the company's stock after buying an additional 3,336,964 shares during the quarter. Bank of America Corp DE owned about 6.55% of Ginkgo Bioworks worth $36,967,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of DNA. SBI Securities Co. Ltd. bought a new position in shares of Ginkgo Bioworks during the 4th quarter worth approximately $29,000. KBC Group NV acquired a new stake in Ginkgo Bioworks in the 4th quarter valued at $31,000. Price T Rowe Associates Inc. MD lifted its position in Ginkgo Bioworks by 4.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 82,815 shares of the company's stock worth $814,000 after buying an additional 3,152 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Ginkgo Bioworks in the fourth quarter valued at approximately $46,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Ginkgo Bioworks by 48.2% in the fourth quarter. Bank of New York Mellon Corp now owns 23,061 shares of the company's stock valued at $226,000 after buying an additional 7,503 shares in the last quarter. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Stock Performance

NYSE:DNA traded up $0.14 during mid-day trading on Monday, hitting $8.07. The stock had a trading volume of 656,934 shares, compared to its average volume of 1,462,219. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.00 and a twelve month high of $33.20. The stock has a market cap of $468.33 million, a price-to-earnings ratio of -0.62 and a beta of 1.29. The company's 50 day simple moving average is $7.17 and its 200 day simple moving average is $9.08.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.35). The firm had revenue of $48.32 million for the quarter, compared to analyst estimates of $38.70 million. Ginkgo Bioworks had a negative return on equity of 58.54% and a negative net margin of 298.78%. As a group, equities analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.